title: Alkylation of prohibitin by cyclohexylphenyl-chloroethyl urea on an aspartyl residue is associated with cell cycle G(1) arrest in B16 cells.
abstract: OBJECTIVE
  Phenyl-chloroethyl ureas (CEUs) are a class of anticancer drugs that mainly react with proteins. Two molecules of this family, cyclohexylphenyl-chloroethyl urea (CCEU) and iodophenyl-chloroethyl urea (ICEU) induced G(1)/S and G(2)/M cell cycle blocks, respectively. We hypothesised that these observations were linked to a differential protein alkylation pattern.
  
  
  METHODS
  Proteins from B16 cells incubated with [(14)C-urea]-CCEU and [(125)I]-ICEU were compared by 2D-analyses followed by MALDI-TOF identification of modified proteins and characterisation of the CCEU binding. Protein expression was investigated by Western blot analyses and cell cycle data were obtained by flow cytometry.
  
  
  RESULTS
  Several proteins (PDIA1, PDIA3, PDIA6, TRX, VDAC2) were alkylated by both ICEU and CCEU but beta-tubulin and prohibitin (PHB) were specifically alkylated by either ICEU or CCEU respectively. Specific alkylation of these two proteins might explain the observed difference in B16 cell cycle arrest in G(2) and G(1) phases respectively. Mass spectrometry studies on the alkylated prohibitin localised the modified peptide and identified Asp-40 as the target for CCEU. This alkylation induced an increased cellular content of PHB that should contribute to the accumulation of cells in G(1) phase.
  
  
  CONCLUSIONS
  This study reinforces our findings that CEUs alkylate proteins through an ester linkage with an acidic amino acid and shows that PHB alkylation contributes to G(1)/S arrest in CCEU treated B16 cells. Modification of PHB status and/or activity is an open route for new cancer therapeutics.
authors: University Clermont 1, UFR Pharmacie, Clermont-Ferrand, France.
authors: B
authors: B
authors: Bouchon
authors: J
authors: J
authors: Papon
authors: Y
authors: Y
authors: Communal
authors: J-C
authors: JC
authors: Madelmont
authors: F
authors: F
authors: Degoul
mesh_terms: D000477:Alkylating Agents / Q000737:chemistry / Q000494:pharmacology; D000478:Alkylation / Q000187:drug effects; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D001224:Aspartic Acid / Q000378:metabolism*; D002250:Carbon Radioisotopes; D002453:Cell Cycle / Q000187:drug effects*; D045744:Cell Line, Tumor; D015180:Electrophoresis, Gel, Two-Dimensional; D005434:Flow Cytometry; D016193:G1 Phase / Q000187:drug effects; D015151:Immunoblotting; D007457:Iodine Radioisotopes; D015394:Molecular Structure; D000091402:Prohibitins; D040901:Proteomics / Q000379:methods; D012097:Repressor Proteins / Q000378:metabolism*; D016196:S Phase / Q000187:drug effects; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods; D014404:Tubulin / Q000378:metabolism; D014508:Urea / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D050994:Voltage-Dependent Anion Channels / Q000378:metabolism
chemical_list: D000477:Alkylating Agents; D000970:Antineoplastic Agents; D002250:Carbon Radioisotopes; D007457:Iodine Radioisotopes; D000091402:Prohibitins; D012097:Repressor Proteins; D014404:Tubulin; D050994:Voltage-Dependent Anion Channels; C527418:cyclohexylphenyl-chloroethyl urea; C527419:iodophenyl-chloroethyl urea; D001224:Aspartic Acid; D014508:Urea
references: Cancer Res. 2000 Feb 15;60(4):985-92
references: 10706114
references: Bioorg Med Chem. 2007 Feb 1;15(3):1430-8
references: 17118664
references: J Med Chem. 2001 Mar 1;44(5):694-702
references: 11262080
references: EMBO Rep. 2002 Feb;3(2):136-40
references: 11839698
references: Cell Mol Life Sci. 2002 Jan;59(1):143-55
references: 11852914
references: Cancer Chemother Pharmacol. 2003 Jun;51(6):474-82
references: 12700925
references: Cancer Res. 2003 Sep 1;63(17):5251-6
references: 14500355
references: J Med Chem. 2003 Nov 6;46(23):5055-63
references: 14584955
references: J Biol Chem. 2003 Nov 28;278(48):47853-61
references: 14500729
references: Biochem Biophys Res Commun. 2003 Dec 12;312(2):459-66
references: 14637159
references: Nature. 2004 Mar 11;428(6979):198-202
references: 15014504
references: EMBO J. 2004 Jun 2;23(11):2293-303
references: 15141164
references: Cancer Res. 2004 Jul 1;64(13):4654-63
references: 15231678
references: Invest New Drugs. 2004 Nov;22(4):369-78
references: 15292707
references: Anticancer Res. 1988 Jul-Aug;8(4):595-8
references: 3052247
references: Cancer Chemother Pharmacol. 1994;33(6):489-92
references: 8137459
references: Trends Mol Med. 2005 Apr;11(4):192-7
references: 15823758
references: Mol Pharmacol. 2005 Nov;68(5):1415-22
references: 16099845
references: J Biol Chem. 2006 Feb 3;281(5):2951-9
references: 16319068
references: J Cell Mol Med. 2006 Apr-Jun;10(2):353-63
references: 16796804
references: Cancer Res. 2006 Jul 15;66(14):7361-9
references: 16849588
references: EMBO J. 2000 Jun 1;19(11):2444-51
references: 10835343